Drug Research

关注

GLP-1 Drugs Halve Cardiac Risk

由 AI 报道

Recent research showed that GLP-1 receptor agonists reduce cardiac event risks by half in certain patient groups. This finding supports expanded use of these drugs beyond diabetes management. The study contributes to ongoing discussions in cardiovascular medicine.

本网站使用 Cookie

我们使用 Cookie 进行分析以改善我们的网站。 阅读我们的 隐私政策 以获取更多信息。
拒绝